Synthetic Biology at Scale: Less Disruption, More Cohesion

For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity
Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients

Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Ingredient Production

Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical production sites.
Antheia secures new funding to boost pharmaceutical ingredients production

The company secured funding through government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside strategic investment from In-Q-Tel and Echo
Secretary of State Antony Blinken visits the Bay Area

Antony Blinken tours Antheia biotech lab, emphasizing its potential to address nationwide medicine shortages by overcoming supply chain issues with advanced bio-technology
Chemicals Knowledge Hub: DCAT Week 2024 Andrea Conforto, VP/Biotech for CDMO at Olon and Zack McGahey, COO at Antheia

In this interview with Antheia and Olon, two leading companies in the life sciences industry, we discussed their ongoing partnership, market trends, and the future of the industry.
PharmaSource: Antheia and Olon Extend Biomanufacturing Partnership

Antheia and Olon have announced a continuation of partnership, leveraging Olon’s fermentation infrastructure for the manufacture of Antheia’s early products
Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines

Antheia and Olon established this partnership in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since played a pivotal role as a CDMO for scaling Antheia’s biomanufacturing processes and producing its Biosynthetic KSMs (key starting materials) and APIs.
Antheia Achieves Major Commercial Milestone

Company’s first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMS and APIs
Introducing Antheia’s Reinvigorated Brand Identity

Since launching Antheia in 2015, we’ve made tremendous strides toward our mission to transform pharmaceutical supply chains for essential medicines. We’ve strengthened our leadership team with veteran executives across R&D, operations, supply chain, and quality and regulatory, we’ve repeatedly validated our technology at commercially-relevant scales, and we are now actively moving into full-scale production to bring our products to market.